Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of fludarabine
and cytarabine that can be given in combination with oxaliplatin and rituximab in the
treatment of chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, or Richter's
transformation. Once the highest tolerable dose for this drug combination is found, the next
goal of the study will be to find out if this combination therapy is effective in shrinking
or slowing the growth of these diseases.